메뉴 건너뛰기




Volumn 75, Issue 3, 2015, Pages 243-251

Pre-Exposure Prophylaxis to Prevent HIV Infection: Current Status, Future Opportunities and Challenges

Author keywords

[No Author keywords available]

Indexed keywords

EMTRICITABINE; TENOFOVIR; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; DRUG COMBINATION;

EID: 84925536173     PISSN: 00126667     EISSN: 11791950     Source Type: Journal    
DOI: 10.1007/s40265-015-0355-4     Document Type: Review
Times cited : (60)

References (75)
  • 1
    • 79961057113 scopus 로고    scopus 로고
    • Estimated HIV incidence in the United States, 2006-2009
    • 1:CAS:528:DC%2BC3MXhtFWitLbP 21826193
    • Prejean J, Song R, Hernandez A, Ziebell R, Green T, Walker F, et al. Estimated HIV incidence in the United States, 2006-2009. PLoS One. 2011;6(8):e17502.
    • (2011) PLoS One. , vol.6 , Issue.8 , pp. 17502
    • Prejean, J.1    Song, R.2    Hernandez, A.3    Ziebell, R.4    Green, T.5    Walker, F.6
  • 2
    • 79451471817 scopus 로고    scopus 로고
    • Joint United Nations Programme on HIV/AIDS (UNAIDS) Accessed 2 Nov 2014
    • UNAIDS report on the global AIDS epidemic 2013. Joint United Nations Programme on HIV/AIDS (UNAIDS). Available at: http://www.unaids.org/en/media/unaids/contentassets/documents/epidemiology/2013/gr2013/UNAIDS-Global-Report-2013-en.pdf. Accessed 2 Nov 2014.
    • UNAIDS Report on the Global AIDS Epidemic 2013
  • 4
    • 84864505868 scopus 로고    scopus 로고
    • Antiretroviral prophylaxis for HIV prevention in heterosexual men and women
    • 1:CAS:528:DC%2BC38XhtlSltrbK 22784037
    • Baeten JM, Donnell D, Ndase P, Mugo NR, Campbell JD, Wangisi J, et al. Antiretroviral prophylaxis for HIV prevention in heterosexual men and women. N Engl J Med. 2012;367(5):399-410.
    • (2012) N Engl J Med. , vol.367 , Issue.5 , pp. 399-410
    • Baeten, J.M.1    Donnell, D.2    Ndase, P.3    Mugo, N.R.4    Campbell, J.D.5    Wangisi, J.6
  • 5
    • 84879000125 scopus 로고    scopus 로고
    • Antiretroviral prophylaxis for HIV infection in injecting drug users in Bangkok, Thailand (the Bangkok Tenofovir Study): A randomised, double-blind, placebo-controlled phase 3 trial
    • Choopanya K, Martin M, Suntharasamai P, Sangkum U, Mock PA, Leethochawalit M, et al. Antiretroviral prophylaxis for HIV infection in injecting drug users in Bangkok, Thailand (the Bangkok Tenofovir Study): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet. 2013;381(9883):2083-90.
    • (2013) Lancet. , vol.381 , Issue.9883 , pp. 2083-2090
    • Choopanya, K.1    Martin, M.2    Suntharasamai, P.3    Sangkum, U.4    Mock, P.A.5    Leethochawalit, M.6
  • 6
    • 78650549662 scopus 로고    scopus 로고
    • Preexposure chemoprophylaxis for HIV prevention in men who have sex with men
    • 1:CAS:528:DC%2BC3MXit1ansg%3D%3D 21091279
    • Grant RM, Lama JR, Anderson PL, McMahan V, Liu AY, Vargas L, et al. Preexposure chemoprophylaxis for HIV prevention in men who have sex with men. N Engl J Med. 2010;363(27):2587-99.
    • (2010) N Engl J Med. , vol.363 , Issue.27 , pp. 2587-2599
    • Grant, R.M.1    Lama, J.R.2    Anderson, P.L.3    McMahan, V.4    Liu, A.Y.5    Vargas, L.6
  • 7
    • 84864527306 scopus 로고    scopus 로고
    • Antiretroviral preexposure prophylaxis for heterosexual HIV transmission in Botswana
    • 1:CAS:528:DC%2BC38XhtlSltrbE 22784038
    • Thigpen MC, Kebaabetswe PM, Paxton LA, Smith DK, Rose CE, Segolodi TM, et al. Antiretroviral preexposure prophylaxis for heterosexual HIV transmission in Botswana. N Engl J Med. 2012;367(5):423-34.
    • (2012) N Engl J Med. , vol.367 , Issue.5 , pp. 423-434
    • Thigpen, M.C.1    Kebaabetswe, P.M.2    Paxton, L.A.3    Smith, D.K.4    Rose, C.E.5    Segolodi, T.M.6
  • 10
    • 84859078297 scopus 로고    scopus 로고
    • Limited awareness and low immediate uptake of pre-exposure prophylaxis among men who have sex with men using an internet social networking site
    • 1:CAS:528:DC%2BC38XlsVagt7s%3D 22470438
    • Krakower DS, Mimiaga MJ, Rosenberger JG, Novak DS, Mitty JA, White JM, et al. Limited awareness and low immediate uptake of pre-exposure prophylaxis among men who have sex with men using an internet social networking site. PLoS One. 2012;7(3):e33119.
    • (2012) PLoS One. , vol.7 , Issue.3 , pp. 33119
    • Krakower, D.S.1    Mimiaga, M.J.2    Rosenberger, J.G.3    Novak, D.S.4    Mitty, J.A.5    White, J.M.6
  • 11
    • 85016821119 scopus 로고    scopus 로고
    • Differences in PrEP knowledge and use in US. MSM users of a popular sexual networking site surveyed in August 2013 and January 2014
    • 28-31 Oct; Cape Town
    • Mayer KH, Oldenburg CE, Novak DS, Krakower DS, Mimiaga MJ. Differences in PrEP knowledge and use in US. MSM users of a popular sexual networking site surveyed in August 2013 and January 2014. R4P Conference; 28-31 Oct 2014; Cape Town.
    • (2014) R4P Conference
    • Mayer, K.H.1    Oldenburg, C.E.2    Novak, D.S.3    Krakower, D.S.4    Mimiaga, M.J.5
  • 12
    • 84925540975 scopus 로고    scopus 로고
    • Lexicomp Accessed 31 Oct 2014
    • Tenofovoir and emtricitabine: drug information. Lexicomp. http://www.uptodate.com/contents/tenofovir-and-emtricitabine-drug-information?source=search-result&search=truvada&selectedTitle=1~80#F3422225. Accessed 31 Oct 2014.
    • Tenofovoir and Emtricitabine: Drug Information
  • 13
    • 84878958898 scopus 로고    scopus 로고
    • Pre-exposure prophylaxis for HIV in women: Daily oral tenofovir, oral tenofovir/emtricitabine, or vaginal tenofovir gel in the VOICE Study (MTN 003)
    • 3-6 Mar; Atlanta Accessed 12 Apr 2013
    • Marrazzo JM, Ramjee G, Nair GB, Palanee T, Mkhiza B, Nakabiito C, et al. Pre-exposure prophylaxis for HIV in women: daily oral tenofovir, oral tenofovir/emtricitabine, or vaginal tenofovir gel in the VOICE Study (MTN 003). Conference on Retroviruses and Opportunistic Infections; 3-6 Mar 2013; Atlanta. Available at: http://www.retroconference.org/2013b/Abstracts/47951.htm. Accessed 12 Apr 2013.
    • (2013) Conference on Retroviruses and Opportunistic Infections
    • Marrazzo, J.M.1    Ramjee, G.2    Nair, G.B.3    Palanee, T.4    Mkhiza, B.5    Nakabiito, C.6
  • 15
    • 84906793896 scopus 로고    scopus 로고
    • Uptake of pre-exposure prophylaxis, sexual practices, and HIV incidence in men and transgender women who have sex with men: A cohort study
    • Grant RM, Anderson PL, McMahan V, Liu A, Amico KR, Mehrotra M, et al. Uptake of pre-exposure prophylaxis, sexual practices, and HIV incidence in men and transgender women who have sex with men: a cohort study. Lancet Infect Dis. 2014;14(9):820-9.
    • (2014) Lancet Infect Dis. , vol.14 , Issue.9 , pp. 820-829
    • Grant, R.M.1    Anderson, P.L.2    McMahan, V.3    Liu, A.4    Amico, K.R.5    Mehrotra, M.6
  • 16
    • 84883461037 scopus 로고    scopus 로고
    • Randomized trial of clinical safety of daily oral tenofovir disoproxil fumarate among Hiv-uninfected men who have sex with men in the United States
    • 1:CAS:528:DC%2BC3sXht12jtLrM 23466649
    • Grohskopf LA, Chillag KL, Gvetadze R, Liu AY, Thompson M, Mayer KH, et al. Randomized trial of clinical safety of daily oral tenofovir disoproxil fumarate among Hiv-uninfected men who have sex with men in the United States. J Acquir Immune Defic Syndr. 2013;64(1):79-86.
    • (2013) J Acquir Immune Defic Syndr. , vol.64 , Issue.1 , pp. 79-86
    • Grohskopf, L.A.1    Chillag, K.L.2    Gvetadze, R.3    Liu, A.Y.4    Thompson, M.5    Mayer, K.H.6
  • 17
    • 84894248922 scopus 로고    scopus 로고
    • Are we prepped for preexposure prophylaxis (PrEP)? Provider opinions on the real-world use of PrEP in the United States and Canada
    • 1:CAS:528:DC%2BC2cXislersrk%3D 24319083
    • Karris MY, Beekmann SE, Mehta SR, Anderson CM, Polgreen PM. Are we prepped for preexposure prophylaxis (PrEP)? Provider opinions on the real-world use of PrEP in the United States and Canada. Clin Infect Dis. 2014;58(5):704-12.
    • (2014) Clin Infect Dis. , vol.58 , Issue.5 , pp. 704-712
    • Karris, M.Y.1    Beekmann, S.E.2    Mehta, S.R.3    Anderson, C.M.4    Polgreen, P.M.5
  • 18
    • 84906317498 scopus 로고    scopus 로고
    • HIV providers' perceived barriers and facilitators to implementing pre-exposure prophylaxis in care settings: A qualitative study
    • Krakower D, Ware N, Mitty JA, Maloney K, Mayer KH. HIV providers' perceived barriers and facilitators to implementing pre-exposure prophylaxis in care settings: a qualitative study. AIDS Behav. 2014;18(9):1712-21.
    • (2014) AIDS Behav. , vol.18 , Issue.9 , pp. 1712-1721
    • Krakower, D.1    Ware, N.2    Mitty, J.A.3    Maloney, K.4    Mayer, K.H.5
  • 19
    • 84877600920 scopus 로고    scopus 로고
    • Attitude towards antiretroviral pre-exposure prophylaxis (PrEP) prescription among HIV specialists
    • Puro V, Palummieri A, De Carli G, Piselli P, Ippolito G. Attitude towards antiretroviral pre-exposure prophylaxis (PrEP) prescription among HIV specialists. BMC Infect Dis. 2013;13:217.
    • (2013) BMC Infect Dis. , vol.13 , pp. 217
    • Puro, V.1    Palummieri, A.2    De Carli, G.3    Piselli, P.4    Ippolito, G.5
  • 20
    • 84885218800 scopus 로고    scopus 로고
    • Pre-exposure prophylaxis (PrEP) for HIV infection: Results of a survey of HIV healthcare providers evaluating their knowledge, attitudes, and prescribing practices
    • Tellalian D, Maznavi K, Bredeek UF, Hardy WD. Pre-exposure prophylaxis (PrEP) for HIV infection: results of a survey of HIV healthcare providers evaluating their knowledge, attitudes, and prescribing practices. AIDS Patient Care STDS. 2013;27(10):553-9.
    • (2013) AIDS Patient Care STDS. , vol.27 , Issue.10 , pp. 553-559
    • Tellalian, D.1    Maznavi, K.2    Bredeek, U.F.3    Hardy, W.D.4
  • 22
    • 77955786301 scopus 로고    scopus 로고
    • Systematic review and meta-analysis: Renal safety of tenofovir disoproxil fumarate in HIV-infected patients
    • 1:CAS:528:DC%2BC3cXhtFyiu7%2FM 20673002
    • Cooper RD, Wiebe N, Smith N, Keiser P, Naicker S, Tonelli M. Systematic review and meta-analysis: renal safety of tenofovir disoproxil fumarate in HIV-infected patients. Clin Infect Dis. 2010;51(5):496-505.
    • (2010) Clin Infect Dis. , vol.51 , Issue.5 , pp. 496-505
    • Cooper, R.D.1    Wiebe, N.2    Smith, N.3    Keiser, P.4    Naicker, S.5    Tonelli, M.6
  • 23
    • 84925540974 scopus 로고    scopus 로고
    • The impact of tenofovir disoproxil fumarate on kidney function: Four-year data from the HIV-infected outpatient cohort
    • 4224877 25394072
    • Monteiro N, Branco M, Peres S, Borges F, Mansinho K. The impact of tenofovir disoproxil fumarate on kidney function: four-year data from the HIV-infected outpatient cohort. J Int AIDS Soc. 2014;17(4 Suppl 3):19565.
    • (2014) J Int AIDS Soc. , vol.17 , Issue.4 , pp. 19565
    • Monteiro, N.1    Branco, M.2    Peres, S.3    Borges, F.4    Mansinho, K.5
  • 24
    • 83455179327 scopus 로고    scopus 로고
    • Pharmacokinetics of antiretroviral drugs in anatomical sanctuary sites: The male and female genital tract
    • 1:CAS:528:DC%2BC38XitVWht7s%3D 22155899
    • Else LJ, Taylor S, Back DJ, Khoo SH. Pharmacokinetics of antiretroviral drugs in anatomical sanctuary sites: the male and female genital tract. Antivir Ther. 2011;16(8):1149-67.
    • (2011) Antivir Ther. , vol.16 , Issue.8 , pp. 1149-1167
    • Else, L.J.1    Taylor, S.2    Back, D.J.3    Khoo, S.H.4
  • 25
    • 34548267289 scopus 로고    scopus 로고
    • Antiretroviral drug exposure in the female genital tract: Implications for oral pre- and post-exposure prophylaxis
    • 1:CAS:528:DC%2BD2sXpsFahsLg%3D 17721097
    • Dumond JB, Yeh RF, Patterson KB, Corbett AH, Jung BH, Rezk NL, et al. Antiretroviral drug exposure in the female genital tract: implications for oral pre- and post-exposure prophylaxis. AIDS. 2007;21(14):1899-907.
    • (2007) AIDS , vol.21 , Issue.14 , pp. 1899-1907
    • Dumond, J.B.1    Yeh, R.F.2    Patterson, K.B.3    Corbett, A.H.4    Jung, B.H.5    Rezk, N.L.6
  • 26
    • 84922475634 scopus 로고    scopus 로고
    • Infection with the frequently transmitted HIV-1 M41L variant has no influence on selection of tenofovir resistance
    • Pingen M, Nijhuis M, Mudrikova T, van Laarhoven A, Langebeek N, Richter C, et al. Infection with the frequently transmitted HIV-1 M41L variant has no influence on selection of tenofovir resistance. J Antimicrob Chemother. 2015;70(2):573-80.
    • (2015) J Antimicrob Chemother. , vol.70 , Issue.2 , pp. 573-580
    • Pingen, M.1    Nijhuis, M.2    Mudrikova, T.3    Van Laarhoven, A.4    Langebeek, N.5    Richter, C.6
  • 27
    • 84873413113 scopus 로고    scopus 로고
    • Tenofovir-based regimens associated with less drug resistance in HIV-1-infected Nigerians failing first-line antiretroviral therapy
    • 1:CAS:528:DC%2BC3sXitVCntbw%3D 23079810
    • Etiebet MA, Shepherd J, Nowak RG, Charurat M, Chang H, Ajayi S, et al. Tenofovir-based regimens associated with less drug resistance in HIV-1-infected Nigerians failing first-line antiretroviral therapy. AIDS. 2013;27(4):553-61.
    • (2013) AIDS , vol.27 , Issue.4 , pp. 553-561
    • Etiebet, M.A.1    Shepherd, J.2    Nowak, R.G.3    Charurat, M.4    Chang, H.5    Ajayi, S.6
  • 29
    • 83155177076 scopus 로고    scopus 로고
    • Penetration of tenofovir and emtricitabine in mucosal tissues: Implications for prevention of HIV-1 transmission
    • Patterson KB, Prince HA, Kraft E, Jenkins AJ, Shaheen NJ, Rooney JF, et al. Penetration of tenofovir and emtricitabine in mucosal tissues: implications for prevention of HIV-1 transmission. Sci Transl Med. 2011;3(112):112re4.
    • (2011) Sci Transl Med. , vol.3 , Issue.112 , pp. 112re4
    • Patterson, K.B.1    Prince, H.A.2    Kraft, E.3    Jenkins, A.J.4    Shaheen, N.J.5    Rooney, J.F.6
  • 30
    • 84904334133 scopus 로고    scopus 로고
    • Incomplete reversibility of estimated glomerular filtration rate decline following tenofovir disoproxil fumarate exposure
    • 1:CAS:528:DC%2BC2cXht1ygtrjJ 24585896
    • Jose S, Hamzah L, Campbell LJ, Hill T, Fisher M, Leen C, et al. Incomplete reversibility of estimated glomerular filtration rate decline following tenofovir disoproxil fumarate exposure. J Infect Dis. 2014;210(3):363-73.
    • (2014) J Infect Dis. , vol.210 , Issue.3 , pp. 363-373
    • Jose, S.1    Hamzah, L.2    Campbell, L.J.3    Hill, T.4    Fisher, M.5    Leen, C.6
  • 31
    • 84906536813 scopus 로고    scopus 로고
    • Long-term exposure to tenofovir continuously decrease renal function in HIV-1-infected patients with low body weight: Results from 10 years of follow-up
    • 1:CAS:528:DC%2BC2cXhslWitLnN 25259702
    • Nishijima T, Kawasaki Y, Tanaka N, Mizushima D, Aoki T, Watanabe K, et al. Long-term exposure to tenofovir continuously decrease renal function in HIV-1-infected patients with low body weight: results from 10 years of follow-up. AIDS. 2014;28(13):1903-10.
    • (2014) AIDS. , vol.28 , Issue.13 , pp. 1903-1910
    • Nishijima, T.1    Kawasaki, Y.2    Tanaka, N.3    Mizushima, D.4    Aoki, T.5    Watanabe, K.6
  • 32
    • 79957494036 scopus 로고    scopus 로고
    • Bone mineral density and fractures in antiretroviral-naive persons randomized to receive abacavir-lamivudine or tenofovir disoproxil fumarate-emtricitabine along with efavirenz or atazanavir-ritonavir: Aids Clinical Trials Group A5224s, a substudy of ACTG A5202
    • 1:CAS:528:DC%2BC3MXmvFChsbk%3D 21606537
    • McComsey GA, Kitch D, Daar ES, Tierney C, Jahed NC, Tebas P, et al. Bone mineral density and fractures in antiretroviral-naive persons randomized to receive abacavir-lamivudine or tenofovir disoproxil fumarate-emtricitabine along with efavirenz or atazanavir-ritonavir: Aids Clinical Trials Group A5224s, a substudy of ACTG A5202. J Infect Dis. 2011;203(12):1791-801.
    • (2011) J Infect Dis. , vol.203 , Issue.12 , pp. 1791-1801
    • McComsey, G.A.1    Kitch, D.2    Daar, E.S.3    Tierney, C.4    Jahed, N.C.5    Tebas, P.6
  • 33
    • 84884500081 scopus 로고    scopus 로고
    • Changes in bone mineral density over a 2-year period in HIV-1-infected men under combined antiretroviral therapy with osteopenia
    • 1:CAS:528:DC%2BC3sXhsVKgsr%2FL 24029735
    • Assoumou L, Katlama C, Viard JP, Bentata M, Simon A, Roux C, et al. Changes in bone mineral density over a 2-year period in HIV-1-infected men under combined antiretroviral therapy with osteopenia. AIDS. 2013;27(15):2425-30.
    • (2013) AIDS. , vol.27 , Issue.15 , pp. 2425-2430
    • Assoumou, L.1    Katlama, C.2    Viard, J.P.3    Bentata, M.4    Simon, A.5    Roux, C.6
  • 34
    • 84906271688 scopus 로고    scopus 로고
    • Renal function of participants in the Bangkok tenofovir study: Thailand, 2005-2012
    • 1:CAS:528:DC%2BC2cXhslCht7vL 24829212
    • Martin M, Vanichseni S, Suntharasamai P, Sangkum U, Mock PA, Gvetadze RJ, et al. Renal function of participants in the Bangkok tenofovir study: Thailand, 2005-2012. Clin Infect Dis. 2014;59(5):716-24.
    • (2014) Clin Infect Dis. , vol.59 , Issue.5 , pp. 716-724
    • Martin, M.1    Vanichseni, S.2    Suntharasamai, P.3    Sangkum, U.4    Mock, P.A.5    Gvetadze, R.J.6
  • 35
    • 84898016347 scopus 로고    scopus 로고
    • Changes in renal function associated with oral emtricitabine/tenofovir disoproxil fumarate use for HIV pre-exposure prophylaxis
    • 1:CAS:528:DC%2BC2cXktlSqtrs%3D 24499951
    • Solomon MM, Lama JR, Glidden DV, Mulligan K, McMahan V, Liu AY, et al. Changes in renal function associated with oral emtricitabine/tenofovir disoproxil fumarate use for HIV pre-exposure prophylaxis. AIDS. 2014;28(6):851-9.
    • (2014) AIDS. , vol.28 , Issue.6 , pp. 851-859
    • Solomon, M.M.1    Lama, J.R.2    Glidden, D.V.3    Mulligan, K.4    McMahan, V.5    Liu, A.Y.6
  • 36
    • 84898738640 scopus 로고    scopus 로고
    • Bone mineral density changes among HIV-uninfected young adults in a randomised trial of pre-exposure prophylaxis with tenofovir-emtricitabine or placebo in Botswana
    • Kasonde M, Niska RW, Rose C, Henderson FL, Segolodi TM, Turner K, et al. Bone mineral density changes among HIV-uninfected young adults in a randomised trial of pre-exposure prophylaxis with tenofovir-emtricitabine or placebo in Botswana. PLoS One. 2014;9(3):e90111.
    • (2014) PLoS One. , vol.9 , Issue.3 , pp. 90111
    • Kasonde, M.1    Niska, R.W.2    Rose, C.3    Henderson, F.L.4    Segolodi, T.M.5    Turner, K.6
  • 37
    • 80052279128 scopus 로고    scopus 로고
    • Bone mineral density in HIV-negative men participating in a tenofovir pre-exposure prophylaxis randomized clinical trial in San Francisco
    • 1:CAS:528:DC%2BC3MXht1Sqt7fL 21897852
    • Liu AY, Vittinghoff E, Sellmeyer DE, Irvin R, Mulligan K, Mayer K, et al. Bone mineral density in HIV-negative men participating in a tenofovir pre-exposure prophylaxis randomized clinical trial in San Francisco. PLoS One. 2011;6(8):e23688.
    • (2011) PLoS One. , vol.6 , Issue.8 , pp. 23688
    • Liu, A.Y.1    Vittinghoff, E.2    Sellmeyer, D.E.3    Irvin, R.4    Mulligan, K.5    Mayer, K.6
  • 38
    • 84925540973 scopus 로고    scopus 로고
    • High levels of interest in PrEP and baseline risk behaviors among MSM enrolled in the US PrEP Demonstration (Demo) project [abstract THPE187]
    • 20-25 Jul 2014; Melbourne
    • Elion R, Doblecki-Lewis S, Cohen S, Castro J, Buchbinder S, Estrada Y, et al. High levels of interest in PrEP and baseline risk behaviors among MSM enrolled in the US PrEP Demonstration (Demo) project [abstract THPE187]. Presented at the 20th International AIDS Conference; 20-25 Jul 2014; Melbourne.
    • 20th International AIDS Conference
    • Elion, R.1    Doblecki-Lewis, S.2    Cohen, S.3    Castro, J.4    Buchbinder, S.5    Estrada, Y.6
  • 42
    • 79251646972 scopus 로고    scopus 로고
    • Interim guidance: preexposure prophylaxis for the prevention of HIV infection in men who have sex with men
    • Interim guidance: preexposure prophylaxis for the prevention of HIV infection in men who have sex with men. MMWR Morb Mortal Wkly Rep. 2011;60(3):65-8.
    • (2011) MMWR Morb Mortal Wkly Rep , vol.60 , Issue.3 , pp. 65-68
  • 43
    • 84925540969 scopus 로고    scopus 로고
    • Early adopters: Socio-demographic and behavioral correlates of chemoprophylaxis use in a recent national online sample of men who have sex with men in the US
    • [abstract no. 954].Presented at the 3-6 Mar 2014; Boston
    • Mayer KH, Oldenburg CE, Novak D, Elsesser S, Krakower DS, Mimiaga MJ. Early adopters: socio-demographic and behavioral correlates of chemoprophylaxis use in a recent national online sample of men who have sex with men in the US [abstract no. 954].Presented at the 21st Conference on Retroviruses and Opportunistic Infections; 3-6 Mar 2014; Boston.
    • 21st Conference on Retroviruses and Opportunistic Infections
    • Mayer, K.H.1    Oldenburg, C.E.2    Novak, D.3    Elsesser, S.4    Krakower, D.S.5    Mimiaga, M.J.6
  • 44
    • 84882973078 scopus 로고    scopus 로고
    • The training needs of general practitioners in the exploration of sexual health matters and providing sexual healthcare to lesbian, gay and bisexual patients
    • Stott DB. The training needs of general practitioners in the exploration of sexual health matters and providing sexual healthcare to lesbian, gay and bisexual patients. Med Teach. 2013;35(9):752-9.
    • (2013) Med Teach. , vol.35 , Issue.9 , pp. 752-759
    • Stott, D.B.1
  • 45
    • 84901606377 scopus 로고    scopus 로고
    • Communication between VA providers and sexual and gender minority veterans: A pilot study
    • Sherman MD, Kauth MR, Shipherd JC, Street RL Jr. Communication between VA providers and sexual and gender minority veterans: a pilot study. Psychol Serv. 2014;11(2):235-42.
    • (2014) Psychol Serv. , vol.11 , Issue.2 , pp. 235-242
    • Sherman, M.D.1    Kauth, M.R.2    Shipherd, J.C.3    Street, Jr.R.L.4
  • 46
    • 84969143099 scopus 로고    scopus 로고
    • Provider beliefs and practices about assessing sexual orientation in two veterans health affairs hospitals
    • Sherman MD, Kauth MR, Shipherd JC, Street RL. Provider beliefs and practices about assessing sexual orientation in two veterans health affairs hospitals. LGBT Health. 2014;1(3):185-91.
    • (2014) LGBT Health. , vol.1 , Issue.3 , pp. 185-191
    • Sherman, M.D.1    Kauth, M.R.2    Shipherd, J.C.3    Street, R.L.4
  • 47
    • 84925540968 scopus 로고    scopus 로고
    • Accessed 16 Oct 2014
    • Gilead Sciences. Paying for Truvada. Available at: http://www.truvada.com/truvada-patient-assistance. Accessed 16 Oct 2014.
    • Gilead Sciences. Paying for Truvada
  • 48
  • 50
    • 84916230041 scopus 로고    scopus 로고
    • Perspectives on use of oral and vaginal antiretrovirals for HIV prevention: The VOICE-C qualitative study in Johannesburg, South Africa
    • 4163995 25224610
    • van der Straten A, Stadler J, Luecke E, Laborde N, Hartmann M, Montgomery ET. Perspectives on use of oral and vaginal antiretrovirals for HIV prevention: the VOICE-C qualitative study in Johannesburg, South Africa. J Int AIDS Soc. 2014;17(3 Suppl 2):19146.
    • (2014) J Int AIDS Soc. , vol.17 , Issue.3 , pp. 19146
    • Van Der Straten, A.1    Stadler, J.2    Luecke, E.3    Laborde, N.4    Hartmann, M.5    Montgomery, E.T.6
  • 51
    • 84925540966 scopus 로고    scopus 로고
    • AIDS Healthcare Foundation Accessed 22 Nov 2014
    • AIDS Healthcare Foundation. An open letter to the CDC: What if you're wrong about PrEP? Available at: http://www.aidshealth.org/wp-content/uploads/2014/11/PrEP-CDC-Open-Letter-What-if-Youre-Wrong-on-PrEP-ad-11-2014-DT1.pdf. Accessed 22 Nov 2014.
    • An Open Letter to the CDC: What if you'Re Wrong about PrEP?
  • 52
    • 84941333153 scopus 로고    scopus 로고
    • The New York Times 16 Nov Accessed 22 Nov 2014
    • The New York Times. AIDS group wages lonely fight against pill to prevent H.I.V. 16 Nov 2014. Available at: http://www.nytimes.com/2014/11/17/upshot/aids-group-wages-lonely-fight-against-pill-to-prevent-hiv.html?-r=0&abt=0002&abg=1. Accessed 22 Nov 2014.
    • (2014) AIDS Group Wages Lonely Fight Against Pill to Prevent H.I.V.
  • 56
    • 84925541113 scopus 로고    scopus 로고
    • HPTN 069: NEXT-PREP: a phase II randomized maraviroc + tenofovir disoproxil fumarate (MVC + TDF), or tenofovir disoproxil fumarate + Eetricitabine (TDF + FTC) for pre-exposure prophylaxis (PrEP) to prevent HIV transmission in at-risk men who have sex with men and in at-risk women. HIV Prevention Trials Network Accessed 16 Oct 2014
    • HPTN 069: NEXT-PREP: a phase II randomized, double-blind, study of the safety and tolerability of maraviroc (MVC), maraviroc + emtricitabine (MVC + FTC), maraviroc + tenofovir disoproxil fumarate (MVC + TDF), or tenofovir disoproxil fumarate + Eetricitabine (TDF + FTC) for pre-exposure prophylaxis (PrEP) to prevent HIV transmission in at-risk men who have sex with men and in at-risk women. HIV Prevention Trials Network. Available at: http://www.hptn.org/research-studies/hptn069.asp. Accessed 16 Oct 2014.
    • Double-blind, Study of the Safety and Tolerability of Maraviroc (MVC), Maraviroc + Emtricitabine (MVC + FTC)
  • 57
    • 77955930318 scopus 로고    scopus 로고
    • Effectiveness and safety of tenofovir gel, an antiretroviral microbicide, for the prevention of HIV infection in women
    • 1:CAS:528:DC%2BC3cXhtV2hsr%2FI 20643915
    • Abdool Karim Q, Abdool Karim SS, Frohlich JA, Grobler AC, Baxter C, Mansoor LE, et al. Effectiveness and safety of tenofovir gel, an antiretroviral microbicide, for the prevention of HIV infection in women. Science. 2010;329(5996):1168-74.
    • (2010) Science. , vol.329 , Issue.5996 , pp. 1168-1174
    • Abdool Karim, Q.1    Abdool Karim, S.S.2    Frohlich, J.A.3    Grobler, A.C.4    Baxter, C.5    Mansoor, L.E.6
  • 60
    • 84890599203 scopus 로고    scopus 로고
    • The development of rectal microbicides for HIV prevention
    • 1:CAS:528:DC%2BC3sXhvFOnu7zI 24266648
    • McGowan I. The development of rectal microbicides for HIV prevention. Expert Opin Drug Deliv. 2014;11(1):69-82.
    • (2014) Expert Opin Drug Deliv. , vol.11 , Issue.1 , pp. 69-82
    • McGowan, I.1
  • 61
    • 84902200641 scopus 로고    scopus 로고
    • A safety and pharmacokinetic trial assessing delivery of dapivirine from a vaginal ring in healthy women
    • 1:CAS:528:DC%2BC2cXpsVKrsbg%3D 24901365
    • Nel A, Haazen W, Nuttall J, Romano J, Rosenberg Z, van Niekerk N. A safety and pharmacokinetic trial assessing delivery of dapivirine from a vaginal ring in healthy women. AIDS. 2014;28(10):1479-87.
    • (2014) AIDS. , vol.28 , Issue.10 , pp. 1479-1487
    • Nel, A.1    Haazen, W.2    Nuttall, J.3    Romano, J.4    Rosenberg, Z.5    Van Niekerk, N.6
  • 65
    • 84907878697 scopus 로고    scopus 로고
    • A compartmental pharmacokinetic evaluation of long-acting rilpivirine in HIV-negative volunteers for pre-exposure prophylaxis
    • 1:CAS:528:DC%2BC2cXhtVKmtL7P 24862215
    • Jackson AG, Else LJ, Mesquita PM, Egan D, Back DJ, Karolia Z, et al. A compartmental pharmacokinetic evaluation of long-acting rilpivirine in HIV-negative volunteers for pre-exposure prophylaxis. Clin Pharmacol Ther. 2014;96(3):314-23.
    • (2014) Clin Pharmacol Ther. , vol.96 , Issue.3 , pp. 314-323
    • Jackson, A.G.1    Else, L.J.2    Mesquita, P.M.3    Egan, D.4    Back, D.J.5    Karolia, Z.6
  • 66
    • 84925495868 scopus 로고    scopus 로고
    • Selection of rilpivirine-resistant HIV-1 in a seroconverter on long-acting rilpivirine (TMC278LA) from the lowest dose arm of the SSAT 040 Trial
    • Penrose KJ, Parikh UM, Hamanishi KA, Panousis C, Else L, Back D, et al. Selection of rilpivirine-resistant HIV-1 in a seroconverter on long-acting rilpivirine (TMC278LA) from the lowest dose arm of the SSAT 040 Trial. AIDS Res Hum Retroviruses. 2014;30(S1):A69.
    • (2014) AIDS Res Hum Retroviruses. , vol.30 , Issue.S1 , pp. 69
    • Penrose, K.J.1    Parikh, U.M.2    Hamanishi, K.A.3    Panousis, C.4    Else, L.5    Back, D.6
  • 67
    • 84925507017 scopus 로고    scopus 로고
    • Preclinical evaluation of TMC-278 LA, a long-acting formulation of rilpivirine, demonstrates significant protection from vaginal HIV Infection
    • Snyder O, Vincent H, Lachau-Durant S, Kraus G, Williams P, Garcia JV. Preclinical evaluation of TMC-278 LA, a long-acting formulation of rilpivirine, demonstrates significant protection from vaginal HIV Infection. AIDS Res Hum Retroviruses. 2014;30(Suppl 1):A11-2.
    • (2014) AIDS Res Hum Retroviruses. , vol.30 , pp. 11-A12
    • Snyder, O.1    Vincent, H.2    Lachau-Durant, S.3    Kraus, G.4    Williams, P.5    Garcia, J.V.6
  • 68
    • 84925485677 scopus 로고    scopus 로고
    • A phase 1 open label safety, acceptability, pharmacokinetic, and pharmacodynamic study of intramuscular TMC278 la (the MWRI-01 Study)
    • McGowan I, Siegel A, Duffill K, Shetler C, Dezzutti C, Richardson-Harman N, et al. A phase 1 open label safety, acceptability, pharmacokinetic, and pharmacodynamic study of intramuscular TMC278 LA (the MWRI-01 Study). AIDS Res Hum Retroviruses. 2014;30(Suppl 1):A71.
    • (2014) AIDS Res Hum Retroviruses. , vol.30 , pp. 71
    • McGowan, I.1    Siegel, A.2    Duffill, K.3    Shetler, C.4    Dezzutti, C.5    Richardson-Harman, N.6
  • 69
    • 84896769378 scopus 로고    scopus 로고
    • Long-acting integrase inhibitor protects macaques from intrarectal simian/human immunodeficiency virus
    • 1:CAS:528:DC%2BC2cXjsVegs7c%3D 24594934
    • Andrews CD, Spreen WR, Mohri H, Moss L, Ford S, Gettie A, et al. Long-acting integrase inhibitor protects macaques from intrarectal simian/human immunodeficiency virus. Science. 2014;343(6175):1151-4.
    • (2014) Science. , vol.343 , Issue.6175 , pp. 1151-1154
    • Andrews, C.D.1    Spreen, W.R.2    Mohri, H.3    Moss, L.4    Ford, S.5    Gettie, A.6
  • 71
    • 84885934539 scopus 로고    scopus 로고
    • Lack of pharmacokinetic interaction between rilpivirine and integrase inhibitors dolutegravir and GSK1265744
    • 1:CAS:528:DC%2BC3sXhs1Kjtr3K 23979733
    • Ford SL, Gould E, Chen S, Margolis D, Spreen W, Crauwels H, et al. Lack of pharmacokinetic interaction between rilpivirine and integrase inhibitors dolutegravir and GSK1265744. Antimicrob Agents Chemother. 2013;57(11):5472-7.
    • (2013) Antimicrob Agents Chemother. , vol.57 , Issue.11 , pp. 5472-5477
    • Ford, S.L.1    Gould, E.2    Chen, S.3    Margolis, D.4    Spreen, W.5    Crauwels, H.6
  • 72
    • 84890124072 scopus 로고    scopus 로고
    • Multipurpose prevention technologies: Products in development
    • 1:CAS:528:DC%2BC3sXhslWlt7bJ 24188708
    • Friend DR, Clark JT, Kiser PF, Clark MR. Multipurpose prevention technologies: products in development. Antiviral Res. 2013;100(Suppl):S39-47.
    • (2013) Antiviral Res. , vol.100 , pp. 39-S47
    • Friend, D.R.1    Clark, J.T.2    Kiser, P.F.3    Clark, M.R.4
  • 74
    • 80054914741 scopus 로고    scopus 로고
    • UNAIDS December Accessed 22 Nov 2014
    • UNAIDS. 2011-2015 strategy: getting to zero. December 2010. Available at: http://www.unaids.org.ua/files/JC2034-UNAIDS-Strategy-en.pdf. Accessed 22 Nov 2014.
    • (2010) 2011-2015 Strategy: Getting to Zero
  • 75
    • 84925543041 scopus 로고    scopus 로고
    • AIDS Vaccine Advocacy Coalition Accessed 2 Dec 2014
    • AIDS Vaccine Advocacy Coalition. HIV prevention research and development database. Available at: http://www.avac.org/pxrd. Accessed 2 Dec 2014.
    • HIV Prevention Research and Development Database


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.